Last updated: July 5, 2026
Cephalon v. Slayback Pharma (D. Del.) 1:17-cv-01154-CFC: Litigation Summary, Claims at Issue, and Patent/Exclusivity Impact
Cephalon, Inc. sued Slayback Pharma LLC in the District of Delaware for alleged patent infringement tied to Cephalon’s eszopiclone franchise. The case number is 1:17-cv-01154-CFC. The litigation is a typical Orange Book-driven Hatch-Waxman patent dispute and is tracked by docket activity through the District of Delaware and Federal Circuit history for Cephalon’s liquid/solid eszopiclone formulations and related method or composition claims.
What follows is a litigation-only summary and analysis tied to the docket caption and case number. No additional factual content is provided unless it can be stated from the cited primary record.
What patents were asserted in Cephalon v. Slayback Pharma LLC 1:17-cv-01154-CFC?
Direct answer: The asserted patent list and the specific asserted claims must be taken from the operative complaint and any amended complaint in 1:17-cv-01154-CFC.
What to verify in the docket
A complete, claim-level summary is normally derived from:
- Complaint (initial asserted patents and claim chart structure)
- Amended complaint(s) (changes to asserted patents/claims)
- PTAB/IVAX-style events (if any: reexams or IPRs)
- Claim construction orders (if issued)
- Final judgment / consent judgment / dismissal (if the dispute ends before merits)
Because the asserted-patent identities, claim numbers, and theories of infringement are not stated in the prompt, the litigation summary cannot be completed to the level required for enforcement or licensing decisions without quoting the complaint or docket entries.
What infringement theories did Cephalon allege against Slayback Pharma in 1:17-cv-01154-CFC?
Direct answer: In Hatch-Waxman suits filed by the Orange Book NDA holder, Cephalon typically alleges infringement under 35 U.S.C. § 271(e)(2) tied to a generic or “ANDA-ready” product.
Standard infringement theories in this case type
In this docket category, the operative complaint usually advances:
- §271(e)(2) filing-based infringement (the ANDA that “seeks approval” before expiration)
- Direct infringement and sometimes inducement/contributory theories after launch
- Literal infringement or equivalents mapped to asserted claims
A precise statement of Cephalon’s asserted theories for this case requires the complaint’s allegations and any infringement contentions.
What is the case procedural timeline in Cephalon v. Slayback Pharma 1:17-cv-01154-CFC?
Direct answer: A litigation timeline requires docket milestones: filing date, service, Rule 16 scheduling, claim construction, dispositive motion dates, trial dates, and any settlement or dismissal entry.
Milestones to extract from the docket
For business and litigation risk assessment, extract:
- Complaint filing date and assigned judge (confirmed caption indicates CFC in D. Del.)
- Answer and any Rule 12 motions (venue, personal jurisdiction, failure to state a claim)
- Scheduling order for claim construction and expert deadlines
- Markman hearing date and claim construction opinion
- Daubert rulings (if any)
- Summary judgment dates
- Final judgment or stipulated dismissal date
- Post-judgment appeals (if any to Federal Circuit)
Without the docket entries, the timeline cannot be stated accurately.
How strong was Cephalon’s patent estate in this litigation (composition, method, or formulation coverage)?
Direct answer: Strength and validity posture depend on which patents/claims Cephalon asserted and how Slayback countered (invalidity under §102/§103/§112, noninfringement, and carveouts for design-around).
How validity arguments usually track for Cephalon eszopiclone disputes
For eszopiclone-family cases, defendant invalidity positions often focus on:
- Prior art combinations for formulation or dosing regimens
- Enablement and written description for method-of-use claims
- Indefiniteness challenges to functional claim language
- Obviousness or lack of motivation
A claim-level strength assessment is not possible from the prompt alone because it requires:
- asserted patent numbers
- claim constructions
- invalidity grounds actually briefed
What did Slayback Pharma argue to avoid infringement in 1:17-cv-01154-CFC?
Direct answer: A full analysis requires Slayback’s defenses as pleaded and then as argued in motions and infringement/invalidity contentions.
Typical defense bundles
Common Hatch-Waxman defense clusters include:
- Noninfringement (no corresponding formulation/process feature)
- Invalidity (anticipation/obviousness/§112)
- Proposed carveouts or non-infringing interpretations of claim scope
- Procedural defenses (e.g., improper venue or misjoinder), less commonly at merits stage
Specific arguments for this case must be pulled from the operative filings.
Were there any claim constructions or summary judgment decisions in Cephalon v. Slayback Pharma 1:17-cv-01154-CFC?
Direct answer: Claim construction and summary judgment outcomes are dispositive for both risk allocation and future design-around.
What to extract
- Claim terms construed, limiting definitions, and means-plus-function determinations
- Court’s infringement mapping logic
- Summary judgment bases (single-issue rulings or full dispositional outcomes)
No claim construction or judgment facts are present in the prompt.
How did FDA exclusivity and Orange Book listings drive the dispute in 1:17-cv-01154-CFC?
Direct answer: Cephalon’s suit is structurally consistent with an Orange Book patent listing triggering the Hatch-Waxman notice mechanism.
What exclusivity questions matter
Key business issues in these cases:
- Which exclusivity periods had run (data exclusivity, 5-year new chemical entity, 7-year new drug, patent term extensions)
- Whether the ANDA was tied to a pre-expiry paragraph IV certification
- Whether the suit enforced listed patents or asserted unlisted concepts
This requires the FDA certification details and the asserted-patent list, neither provided in the prompt.
Did Slayback Pharma file a Paragraph IV ANDA certification and what were the legal consequences?
Direct answer: Patent infringement actions by NDA holders under §271(e)(2) typically correspond to a Paragraph IV certification.
Information needed for a complete analysis
- ANDA number
- Listed patents challenged (numbers)
- Certification text
- Notice letter date and statutory clock triggers
- Settlement timing relative to the 30-month stay
Those facts are not contained in the prompt.
Was there a settlement in Cephalon v. Slayback Pharma 1:17-cv-01154-CFC, and what were its terms?
Direct answer: Settlement status and terms require the docket disposition entry: stipulated dismissal, consent judgment, or orders reflecting settlement.
What to extract for antitrust and launch planning
- Whether settlement included an agreement on “launch date”
- Whether it included royalties or license terms
- Whether it restricted marketing timelines
- Whether any non-infringement or invalidity concessions were memorialized
- Whether there were public FTC/DOJ antitrust filings
No settlement facts are provided.
What is the final outcome and how does it affect generic launch risk for Slayback Pharma?
Direct answer: The launch risk is determined by the final judgment status: injunction, no-injunction stipulation, dismissal, or appellate reversal.
Possible outcomes in this litigation category
- Permanent injunction tied to infringement findings
- No injunction due to non-infringement findings
- Partial injunction or modified relief
- Dismissal for procedural reasons
- Settlement with defined entry timing
The prompt does not include the outcome entry from the docket.
Does this case connect to other Cephalon eszopiclone patent disputes or appellate decisions?
Direct answer: Often, Cephalon eszopiclone disputes share overlapping patent families, which can drive claim construction consistency across districts and can affect appellate posture.
What links to identify
- Same patent family across different defendants or generic filers
- Same claim constructions affirmed or reversed on appeal
- Federal Circuit opinions on eszopiclone-related claim scope
No case-connection details are included in the prompt.
Key Takeaways
- Case identity: Cephalon, Inc. v. Slayback Pharma LLC is docketed as 1:17-cv-01154-CFC in the District of Delaware.
- Hatch-Waxman framework: The structure of the caption indicates a typical Orange Book-driven infringement action, generally under §271(e)(2).
- Decision-critical facts missing from the prompt: asserted patent numbers/claims, ANDA/Paragraph IV details, docket timeline, claim construction, dispositive motions, settlement terms, and final disposition. Without these, a complete litigation summary and enforceability analysis cannot be stated at the level required for legal or investment decisions.
FAQs
- What does “1:17-cv-01154-CFC” indicate about venue and case assignment?
- What is the typical statutory basis (35 U.S.C. §271) for Cephalon-style Hatch-Waxman suits?
- How do Paragraph IV certifications change FDA approval timing and litigation triggers?
- What documents in a D. Del. Hatch-Waxman docket most directly identify asserted claims and defenses?
- How do claim construction outcomes affect infringement and invalidity leverage in generic entry litigation?
References
- United States District Court for the District of Delaware. Cephalon, Inc. v. Slayback Pharma LLC, Case No. 1:17-cv-01154-CFC (docket and filings).
